Literature DB >> 27540336

Hepatitis D Virus: A Call to Screening.

Joseph Ahn1, Robert G Gish1.   

Abstract

Hepatitis D virus causes an aggressive viral hepatitis with a virulent course of progression to cirrhosis and hepatic decompensation. It relies on hepatitis B coinfection for its pathogenesis and propagation. Hepatitis D virus had become the forgotten virus, with reduced public awareness, medical interest, and research support. Recently, there has been a resurgence of awareness and interest in hepatitis D, with improvements in diagnostic testing and establishment of international collaborative efforts to improve therapy. This article provides a framework to understand the impetus for increased screening as well as to identify key issues toward which collaborative efforts can be directed.

Entities:  

Keywords:  Hepatitis delta; cirrhosis; interferon; pegylated interferon; prenylation inhibitors

Year:  2014        PMID: 27540336      PMCID: PMC4988222     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  79 in total

1.  Virological and clinical characteristics of delta hepatitis in Central Europe.

Authors:  B Heidrich; K Deterding; H L Tillmann; R Raupach; M P Manns; H Wedemeyer
Journal:  J Viral Hepat       Date:  2009-06-28       Impact factor: 3.728

2.  Identification of a prenylation site in delta virus large antigen.

Authors:  J S Glenn; J A Watson; C M Havel; J M White
Journal:  Science       Date:  1992-05-29       Impact factor: 47.728

3.  Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications.

Authors:  M Y Kuo; J Goldberg; L Coates; W Mason; J Gerin; J Taylor
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

4.  Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA.

Authors:  Severin Gudima; Jinhong Chang; Gloria Moraleda; Anna Azvolinsky; John Taylor
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Authors:  Marc Lütgehetmann; Lida V Mancke; Tassilo Volz; Martina Helbig; Lena Allweiss; Till Bornscheuer; Joerg M Pollok; Ansgar W Lohse; J Petersen; Stephan Urban; Maura Dandri
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

6.  Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.

Authors:  Fulya Gunsar; Ulus Salih Akarca; Galip Ersoz; Arzu Celebi Kobak; Zeki Karasu; Gul Yuce; Tankut Ilter; Yucel Batur
Journal:  Antivir Ther       Date:  2005

Review 7.  Hepatitis delta: the rediscovery.

Authors:  Mario Rizzetto; Seyed Moayed Alavian
Journal:  Clin Liver Dis       Date:  2013-07-03       Impact factor: 6.126

8.  Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.

Authors:  S C Hadler; M De Monzon; A Ponzetto; E Anzola; D Rivero; A Mondolfi; A Bracho; D P Francis; M A Gerber; S Thung
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

9.  Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex.

Authors:  Y P Xia; C T Yeh; J H Ou; M M Lai
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Entecavir treatment of chronic hepatitis D.

Authors:  Gökhan Kabaçam; F Oguz Onder; Mustafa Yakut; Gülseren Seven; Senem C Karatayli; Ersin Karatayli; Berna Savas; Ramazan Idilman; A Mithat Bozdayi; Cihan Yurdaydin
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

View more
  1 in total

1.  Development and performance of prototype serologic and molecular tests for hepatitis delta infection.

Authors:  Kelly E Coller; Emily K Butler; Ka-Cheung Luk; Mary A Rodgers; Michael Cassidy; Jeffrey Gersch; Anne L McNamara; Mary C Kuhns; George J Dawson; Lazare Kaptue; Birgit Bremer; Heiner Wedemeyer; Gavin A Cloherty
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.